Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD123+ Acute Myeloid Leukemia”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Early research (Phase 1)UnknownNCT04014881
What this trial is testing

Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.

Who this might be right for
CD123+ Acute Myeloid Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 50
Early research (Phase 1)Not Yet RecruitingNCT07464951
What this trial is testing

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
Stephan Grupp MD PhD 30
Early research (Phase 1)Study completedNCT01632852
What this trial is testing

CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

Who this might be right for
Leukemia, Myeloid, Acute
CSL Limited 30
Very early researchUnknownNCT05574608
What this trial is testing

Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia Recurrent
Affiliated Hospital to Academy of Military Medical Sciences 12
Early research (Phase 1)UnknownNCT03796390
What this trial is testing

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Who this might be right for
Acute Myelocytic Leukemia
Hebei Senlang Biotechnology Inc., Ltd. 15
Early research (Phase 1)Active Not RecruitingNCT03766126
What this trial is testing

Lentivirally Redirected CD123 Autologous T Cells in AML

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, AdultAcute Myeloid Leukemia, Refractory
University of Pennsylvania 22
Testing effectiveness (Phase 2)Looking for participantsNCT06561152
What this trial is testing

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Who this might be right for
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Stanford University 20
Testing effectiveness (Phase 2)Ended earlyNCT02992860
What this trial is testing

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY

Who this might be right for
Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
GWT-TUD GmbH 25
Early research (Phase 1)WithdrawnNCT04106076
What this trial is testing

Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukaemia
Cellectis S.A.
Testing effectiveness (Phase 2)Ended earlyNCT02152956
What this trial is testing

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Who this might be right for
AML
MacroGenics 244
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Very early researchLooking for participantsNCT06201247
What this trial is testing

Off-the-shelf CD123 CAR-NK for R/R AML

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Peking University People's Hospital 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04086264
What this trial is testing

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
AbbVie 218
Testing effectiveness (Phase 2)Looking for participantsNCT06125652
What this trial is testing

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Who this might be right for
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
Xuzhou Medical University 20
Early research (Phase 1)Ended earlyNCT05817058
What this trial is testing

First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Affimed GmbH 30
Testing effectiveness (Phase 2)Ended earlyNCT06508489
What this trial is testing

Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

Who this might be right for
Acute Myeloid Leukemia
Sanofi 7
Early research (Phase 1)Active Not RecruitingNCT03190278
What this trial is testing

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia
Cellectis S.A. 29
Testing effectiveness (Phase 2)UnknownNCT04265963
What this trial is testing

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
Chongqing Precision Biotech Co., Ltd 45
Testing effectiveness (Phase 2)Looking for participantsNCT06456463
What this trial is testing

Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Who this might be right for
Acute Myeloid Leukemia
Stemline Therapeutics, Inc. 83
Early research (Phase 1)Looking for participantsNCT06034275
What this trial is testing

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaHigh-risk Myelodysplastic Syndrome
Vincerx Pharma, Inc. 36
Load More Results